search
Back to results

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Primary Purpose

Dry Eye

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Reproxalap Ophthalmic Solution (0.25%) QID
Vehicle Ophthalmic Solution QID
Reproxalap Ophthalmic Solution (0.25%) QID to BID
Vehicle Ophthalmic Solution QID to BID
Sponsored by
Aldeyra Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be at least 18 years of age of either gender and any race;
  • Have a reported history of dry eye for at least 6 months prior to Visit 1;
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1

Exclusion Criteria:

  • Have any clinically significant slit-lamp findings at Visit 1, including active blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active ocular allergies that require therapeutic treatment, or, in the opinion of the investigator may interfere with the assessment of the safety or efficacy of reproxalap or vehicle;
  • Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have used any eye drops within 2 hours of Visit 1;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Have used ophthalmic cyclosporine or lifitigrast 5.0% ophthalmic solution within 90 days of Visit 1;
  • Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
  • Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or anticipate their use during the study period

Sites / Locations

  • Eye Research Foundation

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Reproxalap Ophthalmic Solution (0.25%) QID

Vehicle Ophthalmic Solution QID

Reproxalap Ophthalmic Solution (0.25%) QID to BID

Vehicle Ophthalmic Solution QID to BID

Arm Description

Outcomes

Primary Outcome Measures

Subject-reported ocular dryness score (0 - 100 VAS)
The method of assessment is subject-reported ocular dryness score (0 - 100 VAS)
Fluorescein nasal region score (Ora Calibra® scale)
The method of assessment is Fluorescein nasal region score (Ora Calibra® scale)

Secondary Outcome Measures

Fluorescein staining
The method of assessment for this outcome is the Fluorescein staining Ora Calibra®
Unanesthetized Schirmer's Test
The method of assessment for this outcome is the Schirmer test strip.

Full Information

First Posted
March 15, 2019
Last Updated
December 2, 2020
Sponsor
Aldeyra Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03879863
Brief Title
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Official Title
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
April 16, 2019 (Actual)
Primary Completion Date
October 4, 2019 (Actual)
Study Completion Date
October 4, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aldeyra Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
406 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Reproxalap Ophthalmic Solution (0.25%) QID
Arm Type
Experimental
Arm Title
Vehicle Ophthalmic Solution QID
Arm Type
Placebo Comparator
Arm Title
Reproxalap Ophthalmic Solution (0.25%) QID to BID
Arm Type
Experimental
Arm Title
Vehicle Ophthalmic Solution QID to BID
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Reproxalap Ophthalmic Solution (0.25%) QID
Intervention Description
Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
Intervention Type
Drug
Intervention Name(s)
Vehicle Ophthalmic Solution QID
Intervention Description
Vehicle Ophthalmic Solution administered QID for twelve weeks
Intervention Type
Drug
Intervention Name(s)
Reproxalap Ophthalmic Solution (0.25%) QID to BID
Intervention Description
Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
Intervention Type
Drug
Intervention Name(s)
Vehicle Ophthalmic Solution QID to BID
Intervention Description
Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Primary Outcome Measure Information:
Title
Subject-reported ocular dryness score (0 - 100 VAS)
Description
The method of assessment is subject-reported ocular dryness score (0 - 100 VAS)
Time Frame
Efficacy assessment period (Week 2 through Week 12)
Title
Fluorescein nasal region score (Ora Calibra® scale)
Description
The method of assessment is Fluorescein nasal region score (Ora Calibra® scale)
Time Frame
Efficacy assessment period (Week 2 through Week 12)
Secondary Outcome Measure Information:
Title
Fluorescein staining
Description
The method of assessment for this outcome is the Fluorescein staining Ora Calibra®
Time Frame
Efficacy assessment period (Week 2 through Week 12)
Title
Unanesthetized Schirmer's Test
Description
The method of assessment for this outcome is the Schirmer test strip.
Time Frame
Efficacy assessment period (Week 2 through Week 12)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be at least 18 years of age of either gender and any race; Have a reported history of dry eye for at least 6 months prior to Visit 1; Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1 Exclusion Criteria: Have any clinically significant slit-lamp findings at Visit 1, including active blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active ocular allergies that require therapeutic treatment, or, in the opinion of the investigator may interfere with the assessment of the safety or efficacy of reproxalap or vehicle; Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1; Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study; Have used any eye drops within 2 hours of Visit 1; Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months; Have used ophthalmic cyclosporine or lifitigrast 5.0% ophthalmic solution within 90 days of Visit 1; Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1; Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or anticipate their use during the study period
Facility Information:
Facility Name
Eye Research Foundation
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

We'll reach out to this number within 24 hrs